DelveInsight’s “Optic Atrophy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Optic Atrophy, historical and forecasted epidemiology as well as the Optic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Optic Atrophy market report provides current treatment practices, emerging drugs, Optic Atrophy market share of the individual therapies, and current and forecasted Optic Atrophy market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Optic Atrophy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Key Benefits of the Optic Atrophy Market Report
-
The report covers the descriptive overview of Optic Atrophy, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
-
Comprehensive insight has been provided into the Optic Atrophy epidemiology and treatment in the 7MM
-
Additionally, an all-inclusive account of both the current and emerging therapies for Optic Atrophy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
-
A detailed review of Optic Atrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
-
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Optic Atrophy market
Got queries? Click here to know more about the Optic Atrophy Market Landscape
Optic Atrophy Overview
Optic atrophy refers to the death of the retinal ganglion cell axons that comprise the optic nerve with the resulting picture of a pale optic nerve on fundoscopy. Optic atrophy is an end-stage that arises from myriad causes of optic nerve damage anywhere along the path from the retina to the lateral geniculate. Since the optic nerve transmits retinal information to the brain, optic atrophy is associated with vision loss. Optic atrophy is somewhat of a misnomer as atrophy implies disuse, and thus optic nerve damage is better termed optic neuropathy.
Clinically, optic atrophy manifests as changes in the color and the structure of the optic disc (cupping) associated with variable degrees of visual dysfunction. The term “atrophy” is a misnomer, since, in its strict histologic definition, atrophy implies involution of a structure due to prolonged disuse
Optic Atrophy Epidemiological Insights:
-
The prevalence of optic atrophy varies widely. Optic atrophy was one of the five main causes of blindness in prevalence studies from Israel, Japan, Scotland, Zaire, and other countries. In the Oman eye study, 5% of blindness was attributable to this condition.[ In a study from Egypt, the age-adjusted blindness prevalence rates per 1000 persons showed that in an urban population, 4.1% of the blindness, and in a rural population 1.2% of the blindness was attributable to optic atrophy.
-
In southern Germany, newly-registered blindness-allowance recipients were analyzed for the causes of blindness. Among the 3531 individuals, the standardized incidence rate per 100,000 person-years for optic atrophy was 2.86 (SD 2.66-3.05). In a study from the Baltimore area of the United States, the prevalence of blindness due to optic atrophy in whites was found to be zero, while it was 1.9% in African-Americans, giving a total prevalence of 0.8% across both groups. In another population-based study from the United States, 0.83% of individuals were found to be bilaterally blind. Of these, optic atrophy was responsible for bilateral blindness in 3 persons.
Optic Atrophy Epidemiological Segmentation
-
Optic Atrophy Market prevelant cases
-
Optic Atrophy Market diagnostic cases
-
Optic Atrophy Market gender-specific cases
Optic Atrophy Market Outlook
The Optic Atrophy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Optic Atrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of the Optic Atrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Optic Atrophy market in 7MM is expected to change in the study period 2019-2032.
Learn more by requesting for sample @ Optic Atrophy Market Landscape
Optic Atrophy Key Companies
-
Quark Pharmaceuticals
-
Gensight Pharmaceuticals
-
Santhera Pharmaceuticals
-
Okuvision Gmbh
-
And many others
Optic Atrophy Key Therapies
-
QPI-1007
-
Curcumin
-
rAAV2-ND4
-
GS010
-
And many others
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of Optic Atrophy Market
-
Disease Background and Overview
-
Epidemiology and patient population
-
The United States
-
EU 5
-
Optic Atrophy Market Emerging Therapies
-
Optic Atrophy Market Market Outlook
-
Market Drivers
-
Market Barriers
-
Market Access and Reimbursement of Therapies
-
Appendix
-
Optic Atrophy Market Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
-
About DelveInsight
Click here to read more about Optic Atrophy Market Landscape
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/